NCT04572152View on ClinicalTrials.gov

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

May 2, 2023

Study Completion Date

August 31, 2023

Conditions
Advanced or Metastatic Solid Tumors
Interventions
BIOLOGICAL

AK119

Subjects will receive AK119 by intravenous administration.

BIOLOGICAL

AK104

On the same day subjects will receive AK104 by intravenous administration.

Trial Locations (5)

2148

Blacktown Cancer and Haematology Centre (Blacktown Hospital), Blacktown

3004

Alfred Health (The Alfred Hospital), Melbourne

3168

Monash Health, Clayton

4101

ICON Cancer Centre, South Brisbane

5037

Ashford Cancer Centre, Adelaide

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY